 Casey Greene
Concepts (418)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 32 | 2025 | 669 | 5.410 |
Why?
| | Gene Expression Profiling | 24 | 2026 | 1767 | 3.950 |
Why?
| | Single-Cell Analysis | 10 | 2026 | 362 | 3.600 |
Why?
| | Software | 18 | 2026 | 680 | 2.970 |
Why?
| | Machine Learning | 18 | 2024 | 587 | 2.670 |
Why?
| | Transcriptome | 21 | 2026 | 1038 | 2.550 |
Why?
| | Genomics | 18 | 2025 | 825 | 2.540 |
Why?
| | Sequence Analysis, RNA | 9 | 2026 | 442 | 2.340 |
Why?
| | Algorithms | 18 | 2025 | 1845 | 2.110 |
Why?
| | Gene Regulatory Networks | 10 | 2024 | 317 | 2.100 |
Why?
| | Information Dissemination | 6 | 2020 | 224 | 2.090 |
Why?
| | Epistasis, Genetic | 6 | 2023 | 63 | 1.610 |
Why?
| | Data Mining | 5 | 2018 | 113 | 1.520 |
Why?
| | Neoplasms | 13 | 2026 | 2906 | 1.500 |
Why?
| | Biomedical Research | 5 | 2025 | 717 | 1.500 |
Why?
| | Pseudomonas aeruginosa | 7 | 2024 | 395 | 1.460 |
Why?
| | Ovarian Neoplasms | 9 | 2025 | 595 | 1.440 |
Why?
| | Viral Vaccines | 2 | 2023 | 107 | 1.400 |
Why?
| | Rare Diseases | 2 | 2023 | 116 | 1.280 |
Why?
| | Databases, Genetic | 13 | 2022 | 238 | 1.260 |
Why?
| | Gene Expression | 4 | 2023 | 1476 | 1.090 |
Why?
| | Research Personnel | 2 | 2020 | 184 | 1.040 |
Why?
| | Genome-Wide Association Study | 10 | 2021 | 1407 | 1.010 |
Why?
| | Humans | 106 | 2026 | 145475 | 0.910 |
Why?
| | Natural Language Processing | 2 | 2024 | 106 | 0.890 |
Why?
| | Peer Review, Research | 2 | 2022 | 36 | 0.870 |
Why?
| | Nonlinear Dynamics | 2 | 2023 | 92 | 0.860 |
Why?
| | Journalism | 1 | 2024 | 5 | 0.840 |
Why?
| | Direct-To-Consumer Screening and Testing | 1 | 2024 | 2 | 0.830 |
Why?
| | Breeding | 1 | 2024 | 63 | 0.810 |
Why?
| | Artificial Intelligence | 4 | 2024 | 381 | 0.800 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 35 | 0.780 |
Why?
| | Cell Nucleus | 1 | 2026 | 588 | 0.750 |
Why?
| | Cystadenocarcinoma, Serous | 4 | 2025 | 89 | 0.730 |
Why?
| | User-Computer Interface | 4 | 2023 | 165 | 0.710 |
Why?
| | Societies, Scientific | 1 | 2021 | 50 | 0.680 |
Why?
| | Genetic Testing | 1 | 2024 | 480 | 0.660 |
Why?
| | Neurofibromin 1 | 2 | 2019 | 26 | 0.650 |
Why?
| | Metadata | 1 | 2020 | 17 | 0.640 |
Why?
| | Data Compression | 1 | 2020 | 8 | 0.630 |
Why?
| | Guidelines as Topic | 1 | 2022 | 266 | 0.610 |
Why?
| | Computer Simulation | 7 | 2025 | 1003 | 0.590 |
Why?
| | Genetic Association Studies | 3 | 2016 | 369 | 0.590 |
Why?
| | Computer Security | 1 | 2019 | 25 | 0.590 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 530 | 0.570 |
Why?
| | Precision Medicine | 5 | 2024 | 459 | 0.570 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 170 | 0.570 |
Why?
| | Confidentiality | 1 | 2019 | 80 | 0.560 |
Why?
| | Language | 1 | 2022 | 323 | 0.560 |
Why?
| | Scholarly Communication | 1 | 2018 | 4 | 0.550 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 30 | 0.540 |
Why?
| | ras Proteins | 2 | 2019 | 150 | 0.540 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 686 | 0.540 |
Why?
| | Probability | 3 | 2024 | 307 | 0.530 |
Why?
| | Access to Information | 1 | 2018 | 47 | 0.530 |
Why?
| | Biomedical Technology | 1 | 2018 | 50 | 0.520 |
Why?
| | Disease | 3 | 2018 | 96 | 0.510 |
Why?
| | Glioblastoma | 2 | 2019 | 353 | 0.500 |
Why?
| | Gene Silencing | 2 | 2018 | 202 | 0.500 |
Why?
| | alpha-Synuclein | 1 | 2017 | 45 | 0.490 |
Why?
| | Models, Biological | 3 | 2020 | 1764 | 0.490 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.490 |
Why?
| | Parasites | 1 | 2017 | 44 | 0.480 |
Why?
| | Models, Genetic | 5 | 2019 | 524 | 0.480 |
Why?
| | Genome, Human | 6 | 2018 | 420 | 0.480 |
Why?
| | Systems Biology | 3 | 2018 | 69 | 0.470 |
Why?
| | MicroRNAs | 1 | 2022 | 686 | 0.460 |
Why?
| | Gene Ontology | 5 | 2020 | 53 | 0.460 |
Why?
| | Workflow | 1 | 2017 | 183 | 0.450 |
Why?
| | Quantitative Trait, Heritable | 1 | 2016 | 113 | 0.450 |
Why?
| | Research | 1 | 2018 | 430 | 0.440 |
Why?
| | Protein Interaction Maps | 1 | 2015 | 51 | 0.440 |
Why?
| | Unsupervised Machine Learning | 4 | 2024 | 23 | 0.440 |
Why?
| | Neurodegenerative Diseases | 1 | 2017 | 142 | 0.430 |
Why?
| | Bacterial Proteins | 2 | 2020 | 967 | 0.410 |
Why?
| | Authorship | 2 | 2024 | 49 | 0.400 |
Why?
| | Models, Theoretical | 1 | 2017 | 558 | 0.400 |
Why?
| | Internet | 5 | 2023 | 689 | 0.400 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 734 | 0.400 |
Why?
| | Bayes Theorem | 5 | 2018 | 420 | 0.390 |
Why?
| | RNA, Untranslated | 1 | 2014 | 121 | 0.370 |
Why?
| | Microbiota | 2 | 2017 | 730 | 0.350 |
Why?
| | Cluster Analysis | 3 | 2024 | 500 | 0.350 |
Why?
| | Drosophila melanogaster | 5 | 2019 | 237 | 0.340 |
Why?
| | Pandemics | 5 | 2023 | 1707 | 0.340 |
Why?
| | Bibliometrics | 2 | 2024 | 66 | 0.330 |
Why?
| | Signal Transduction | 8 | 2020 | 5216 | 0.330 |
Why?
| | Publishing | 2 | 2024 | 114 | 0.320 |
Why?
| | Writing | 2 | 2024 | 101 | 0.320 |
Why?
| | Embryonic Development | 3 | 2020 | 125 | 0.310 |
Why?
| | Databases, Factual | 2 | 2018 | 1490 | 0.300 |
Why?
| | Molecular Sequence Annotation | 5 | 2023 | 105 | 0.300 |
Why?
| | Animals | 20 | 2026 | 38030 | 0.300 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 95 | 0.290 |
Why?
| | Terminology as Topic | 3 | 2022 | 257 | 0.290 |
Why?
| | Scleroderma, Systemic | 3 | 2017 | 123 | 0.280 |
Why?
| | Supervised Machine Learning | 2 | 2020 | 23 | 0.280 |
Why?
| | Female | 24 | 2025 | 78845 | 0.280 |
Why?
| | Genome | 2 | 2019 | 305 | 0.280 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2158 | 0.260 |
Why?
| | Betacoronavirus | 2 | 2020 | 288 | 0.260 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 934 | 0.250 |
Why?
| | Drosophila Proteins | 2 | 2019 | 213 | 0.240 |
Why?
| | Homologous Recombination | 1 | 2025 | 37 | 0.230 |
Why?
| | Proteomics | 4 | 2021 | 1188 | 0.230 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 368 | 0.220 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 389 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 383 | 0.220 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 293 | 0.220 |
Why?
| | Publications | 2 | 2022 | 47 | 0.210 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3413 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2378 | 0.200 |
Why?
| | Sexism | 1 | 2024 | 68 | 0.200 |
Why?
| | Mice | 12 | 2025 | 18329 | 0.190 |
Why?
| | Science | 1 | 2024 | 55 | 0.190 |
Why?
| | Cystic Fibrosis | 2 | 2024 | 1161 | 0.190 |
Why?
| | Causality | 1 | 2023 | 126 | 0.190 |
Why?
| | Cell Line, Tumor | 4 | 2019 | 3542 | 0.190 |
Why?
| | Breast Neoplasms | 2 | 2015 | 2382 | 0.190 |
Why?
| | Vaccines, Subunit | 1 | 2023 | 53 | 0.190 |
Why?
| | Pedigree | 1 | 2024 | 515 | 0.190 |
Why?
| | Dogs | 1 | 2024 | 458 | 0.180 |
Why?
| | Sample Size | 1 | 2022 | 121 | 0.180 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2019 | 258 | 0.180 |
Why?
| | Mushroom Bodies | 2 | 2019 | 4 | 0.180 |
Why?
| | Hedgehog Proteins | 2 | 2021 | 200 | 0.180 |
Why?
| | Pseudomonas Infections | 1 | 2024 | 230 | 0.170 |
Why?
| | Periodicals as Topic | 1 | 2024 | 209 | 0.170 |
Why?
| | Male | 16 | 2025 | 72843 | 0.170 |
Why?
| | Quality Control | 1 | 2021 | 161 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Neoplasm Grading | 4 | 2025 | 310 | 0.170 |
Why?
| | Fibrosis | 2 | 2021 | 559 | 0.160 |
Why?
| | Cooperative Behavior | 2 | 2021 | 462 | 0.160 |
Why?
| | High-Throughput Screening Assays | 2 | 2014 | 176 | 0.160 |
Why?
| | Gamma Rays | 1 | 2021 | 57 | 0.160 |
Why?
| | Bone Development | 1 | 2021 | 52 | 0.160 |
Why?
| | Linear Models | 1 | 2023 | 845 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 78 | 0.160 |
Why?
| | Medical Informatics | 1 | 2021 | 99 | 0.160 |
Why?
| | Organ Specificity | 3 | 2017 | 309 | 0.160 |
Why?
| | Mutation | 5 | 2025 | 4075 | 0.160 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 18 | 0.160 |
Why?
| | Bone Diseases | 1 | 2021 | 61 | 0.160 |
Why?
| | Hemerythrin | 1 | 2020 | 2 | 0.160 |
Why?
| | Electronic Health Records | 3 | 2018 | 1196 | 0.160 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 928 | 0.160 |
Why?
| | Privacy | 1 | 2020 | 41 | 0.160 |
Why?
| | Histone Code | 1 | 2020 | 39 | 0.150 |
Why?
| | Alzheimer Disease | 2 | 2017 | 630 | 0.150 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1443 | 0.150 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.150 |
Why?
| | Systems Integration | 2 | 2017 | 36 | 0.150 |
Why?
| | Neurofibromatosis 1 | 1 | 2020 | 55 | 0.150 |
Why?
| | Radiation Injuries | 1 | 2021 | 149 | 0.150 |
Why?
| | Phenotype | 4 | 2021 | 3155 | 0.150 |
Why?
| | Genetic Fitness | 1 | 2020 | 56 | 0.150 |
Why?
| | Base Sequence | 1 | 2022 | 2170 | 0.150 |
Why?
| | Cell Hypoxia | 1 | 2020 | 247 | 0.140 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 219 | 0.140 |
Why?
| | Exons | 1 | 2020 | 363 | 0.140 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2597 | 0.140 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 177 | 0.140 |
Why?
| | Biofilms | 2 | 2019 | 292 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2018 | 32 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 399 | 0.140 |
Why?
| | Medulloblastoma | 1 | 2021 | 215 | 0.140 |
Why?
| | Hypertension | 2 | 2019 | 1273 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 534 | 0.140 |
Why?
| | Pseudomonas fluorescens | 1 | 2018 | 3 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 344 | 0.140 |
Why?
| | Proteins | 2 | 2016 | 1023 | 0.140 |
Why?
| | Sex Factors | 1 | 2024 | 2105 | 0.140 |
Why?
| | DNA Repair | 2 | 2011 | 254 | 0.140 |
Why?
| | Atlases as Topic | 1 | 2018 | 10 | 0.130 |
Why?
| | Cyclic GMP | 1 | 2018 | 90 | 0.130 |
Why?
| | Bone and Bones | 1 | 2021 | 317 | 0.130 |
Why?
| | Recombinational DNA Repair | 1 | 2018 | 19 | 0.130 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1321 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2019 | 274 | 0.130 |
Why?
| | Alternative Splicing | 1 | 2020 | 247 | 0.130 |
Why?
| | Down Syndrome | 1 | 2025 | 525 | 0.130 |
Why?
| | Glomerulonephritis | 1 | 2018 | 44 | 0.130 |
Why?
| | Pennsylvania | 1 | 2018 | 138 | 0.130 |
Why?
| | Public Sector | 1 | 2017 | 16 | 0.130 |
Why?
| | False Positive Reactions | 1 | 2018 | 123 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 561 | 0.130 |
Why?
| | Phosphoproteins | 1 | 2019 | 337 | 0.130 |
Why?
| | Starvation | 1 | 2017 | 23 | 0.130 |
Why?
| | Trans-Activators | 1 | 2020 | 396 | 0.130 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 177 | 0.130 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 174 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 441 | 0.130 |
Why?
| | Drug Design | 1 | 2018 | 175 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 767 | 0.120 |
Why?
| | Data Collection | 1 | 2019 | 640 | 0.120 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 123 | 0.120 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 297 | 0.120 |
Why?
| | Genome, Microbial | 1 | 2016 | 7 | 0.120 |
Why?
| | Amygdala | 1 | 2017 | 199 | 0.120 |
Why?
| | Microbial Consortia | 1 | 2016 | 11 | 0.120 |
Why?
| | Multiple Myeloma | 1 | 2019 | 309 | 0.120 |
Why?
| | Body Mass Index | 1 | 2025 | 2445 | 0.120 |
Why?
| | Phylogeny | 1 | 2020 | 917 | 0.120 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 15 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2018 | 749 | 0.110 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2018 | 337 | 0.110 |
Why?
| | Drug Repositioning | 1 | 2015 | 39 | 0.110 |
Why?
| | Blood Pressure | 2 | 2019 | 1779 | 0.110 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 563 | 0.110 |
Why?
| | Memory | 1 | 2017 | 295 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1137 | 0.110 |
Why?
| | Social Behavior | 1 | 2017 | 284 | 0.110 |
Why?
| | Toxicology | 1 | 2015 | 49 | 0.110 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 519 | 0.110 |
Why?
| | Search Engine | 1 | 2015 | 13 | 0.110 |
Why?
| | Knowledge Bases | 1 | 2015 | 28 | 0.110 |
Why?
| | RNA | 4 | 2024 | 910 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1164 | 0.100 |
Why?
| | Pharmacogenetics | 1 | 2015 | 175 | 0.100 |
Why?
| | Metabolome | 1 | 2017 | 388 | 0.100 |
Why?
| | Genes | 3 | 2013 | 227 | 0.100 |
Why?
| | Prognosis | 3 | 2021 | 4316 | 0.100 |
Why?
| | Decision Support Techniques | 1 | 2018 | 477 | 0.100 |
Why?
| | Hospital Mortality | 1 | 2018 | 1038 | 0.100 |
Why?
| | Biological Phenomena | 1 | 2013 | 4 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 270 | 0.100 |
Why?
| | Macrophages | 1 | 2021 | 1507 | 0.100 |
Why?
| | Circadian Rhythm | 1 | 2017 | 512 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2025 | 777 | 0.090 |
Why?
| | Proteome | 1 | 2017 | 514 | 0.090 |
Why?
| | Podocytes | 1 | 2013 | 80 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1747 | 0.090 |
Why?
| | Length of Stay | 1 | 2018 | 1349 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1997 | 0.090 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 401 | 0.090 |
Why?
| | Intensive Care Units | 1 | 2018 | 924 | 0.090 |
Why?
| | Adult | 8 | 2025 | 40777 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 614 | 0.090 |
Why?
| | Brain | 1 | 2024 | 2947 | 0.090 |
Why?
| | Middle Aged | 10 | 2025 | 36215 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 377 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2823 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1374 | 0.080 |
Why?
| | Obesity | 1 | 2025 | 3116 | 0.080 |
Why?
| | Child | 5 | 2026 | 22707 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2018 | 946 | 0.080 |
Why?
| | Bias | 1 | 2012 | 197 | 0.080 |
Why?
| | Aged | 8 | 2025 | 26153 | 0.080 |
Why?
| | Pediatrics | 1 | 2019 | 1121 | 0.080 |
Why?
| | Decision Making | 1 | 2018 | 977 | 0.080 |
Why?
| | Knowledge | 1 | 2010 | 57 | 0.080 |
Why?
| | Multifactor Dimensionality Reduction | 1 | 2010 | 2 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1329 | 0.080 |
Why?
| | Microglia | 2 | 2024 | 270 | 0.080 |
Why?
| | Models, Statistical | 3 | 2020 | 671 | 0.080 |
Why?
| | Memory, Long-Term | 2 | 2019 | 12 | 0.070 |
Why?
| | Transcription Factors | 1 | 2017 | 1734 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2013 | 425 | 0.070 |
Why?
| | Rats | 3 | 2013 | 5584 | 0.070 |
Why?
| | Geography | 1 | 2009 | 187 | 0.070 |
Why?
| | Biopsy | 3 | 2018 | 1082 | 0.070 |
Why?
| | Parkinson Disease | 1 | 2015 | 599 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1419 | 0.070 |
Why?
| | Gene Frequency | 1 | 2009 | 487 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2015 | 4148 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6066 | 0.060 |
Why?
| | Multifactorial Inheritance | 1 | 2008 | 195 | 0.060 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 668 | 0.060 |
Why?
| | United States | 2 | 2021 | 16098 | 0.060 |
Why?
| | Cytokines | 2 | 2018 | 2067 | 0.060 |
Why?
| | Terminal Repeat Sequences | 1 | 2006 | 17 | 0.060 |
Why?
| | Alleles | 1 | 2009 | 894 | 0.060 |
Why?
| | Retroelements | 1 | 2006 | 50 | 0.060 |
Why?
| | Bone Density | 2 | 2021 | 487 | 0.060 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2025 | 39 | 0.050 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2025 | 42 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2009 | 3623 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2019 | 11772 | 0.050 |
Why?
| | Pilot Projects | 2 | 2022 | 1891 | 0.050 |
Why?
| | Europe | 1 | 2025 | 418 | 0.050 |
Why?
| | Culture Media | 1 | 2024 | 161 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 109 | 0.050 |
Why?
| | Microarray Analysis | 1 | 2023 | 116 | 0.050 |
Why?
| | Metals | 1 | 2024 | 136 | 0.050 |
Why?
| | Smoking | 1 | 2010 | 1472 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 507 | 0.050 |
Why?
| | Astrocytes | 1 | 2024 | 228 | 0.040 |
Why?
| | Sputum | 1 | 2024 | 302 | 0.040 |
Why?
| | Budgets | 1 | 2021 | 14 | 0.040 |
Why?
| | Interdisciplinary Research | 1 | 2021 | 26 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5983 | 0.040 |
Why?
| | Gene Library | 1 | 2021 | 122 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 870 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Neurofibroma | 1 | 2020 | 5 | 0.040 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2020 | 13 | 0.040 |
Why?
| | Neurofibroma, Plexiform | 1 | 2020 | 12 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 335 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2021 | 211 | 0.040 |
Why?
| | Osteoblasts | 1 | 2021 | 145 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2019 | 34 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 104 | 0.040 |
Why?
| | Data Accuracy | 1 | 2020 | 65 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 89 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2021 | 506 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 72 | 0.040 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2019 | 5 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 143 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 61 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 465 | 0.040 |
Why?
| | Genome, Fungal | 1 | 2019 | 44 | 0.040 |
Why?
| | Reward | 1 | 2021 | 248 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2025 | 8333 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 886 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 765 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 153 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2019 | 123 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 14219 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 82 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 65 | 0.040 |
Why?
| | Osteogenesis | 1 | 2021 | 204 | 0.040 |
Why?
| | Locomotion | 1 | 2019 | 101 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 165 | 0.030 |
Why?
| | Wilms Tumor | 1 | 2019 | 89 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 378 | 0.030 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 103 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2019 | 335 | 0.030 |
Why?
| | Genes, Neoplasm | 1 | 2018 | 26 | 0.030 |
Why?
| | Two-Hybrid System Techniques | 1 | 2018 | 59 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2019 | 174 | 0.030 |
Why?
| | Pentose Phosphate Pathway | 1 | 2018 | 55 | 0.030 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 52 | 0.030 |
Why?
| | Monocytes | 1 | 2021 | 539 | 0.030 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2018 | 24 | 0.030 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 43 | 0.030 |
Why?
| | Acid Phosphatase | 1 | 2017 | 14 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 307 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 199 | 0.030 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 125 | 0.030 |
Why?
| | Mouth | 1 | 2017 | 86 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2018 | 118 | 0.030 |
Why?
| | Isoenzymes | 1 | 2018 | 294 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 471 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 92 | 0.030 |
Why?
| | GTPase-Activating Proteins | 1 | 2017 | 81 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 133 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 170 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 600 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 447 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 117 | 0.030 |
Why?
| | Chromatin | 1 | 2021 | 553 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 959 | 0.030 |
Why?
| | Databases, Protein | 1 | 2016 | 88 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1138 | 0.030 |
Why?
| | Genetic Loci | 1 | 2017 | 264 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1246 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2016 | 68 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 89 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 2090 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2018 | 382 | 0.030 |
Why?
| | Saliva | 1 | 2017 | 246 | 0.030 |
Why?
| | Blood Proteins | 1 | 2017 | 239 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 730 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 321 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2021 | 740 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 238 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2017 | 298 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1505 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 474 | 0.030 |
Why?
| | DNA Damage | 1 | 2018 | 437 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 832 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2134 | 0.030 |
Why?
| | Esophagus | 1 | 2017 | 262 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 919 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10885 | 0.030 |
Why?
| | Oxygen | 1 | 2020 | 978 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1454 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1061 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 613 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 574 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 910 | 0.030 |
Why?
| | Heart Rate | 1 | 2017 | 855 | 0.020 |
Why?
| | Colorado | 1 | 2024 | 4554 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 688 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2021 | 2507 | 0.020 |
Why?
| | Aging | 1 | 2024 | 1969 | 0.020 |
Why?
| | Regression Analysis | 1 | 2015 | 1001 | 0.020 |
Why?
| | Support Vector Machine | 1 | 2013 | 33 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 981 | 0.020 |
Why?
| | Organogenesis | 1 | 2013 | 63 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2953 | 0.020 |
Why?
| | Nanotechnology | 1 | 2013 | 114 | 0.020 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 171 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2440 | 0.020 |
Why?
| | Risk | 1 | 2015 | 919 | 0.020 |
Why?
| | Computer Graphics | 1 | 2012 | 41 | 0.020 |
Why?
| | Skin | 1 | 2017 | 753 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 405 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 22530 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 972 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 562 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2803 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2013 | 326 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5905 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4560 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 429 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2012 | 314 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 532 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 978 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 1070 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 7123 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 2046 | 0.010 |
Why?
| | Child, Preschool | 1 | 2021 | 11853 | 0.010 |
Why?
| | Lung | 1 | 2017 | 4106 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2878 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2664 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 17291 | 0.010 |
Why?
|
|
Greene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|